Trials / Recruiting
RecruitingNCT06992258
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Criterium, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fruquintinib+ Lonsurf (trifluridine and tipiracil) | Experimental arm |
| DRUG | Fruquintinib | Standard Of Care Arm |
Timeline
- Start date
- 2025-10-27
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
- First posted
- 2025-05-28
- Last updated
- 2026-03-17
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06992258. Inclusion in this directory is not an endorsement.